PIK3CA, one of the most commonly mutated genes in breast cancer, especially in HR+ and HER2+ subtypes, drives hyperactivation of the PI3K/AKT/mTOR pathway, making it a key target for PI3K inhibitors (73, 82, 83). This evidence concerns the gene PIK3CB and breast carcinoma.